The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.
The document outlines the Call's 2027 proposed research scope, eligibility criteria, consortium requirements and preliminary application timetable for multinational collaborations on recently identified rare diseases.
